Literature DB >> 18685352

Opioids for chronic pain: molecular and genomic basis of actions and adverse effects.

Sam H Ahmedzai1, Jason Boland.   

Abstract

PURPOSE OF REVIEW: Opioid analgesics are being increasingly used for pain control in both cancer and noncancer patients. Despite thousands of years of their use, the biological basis of their action and adverse effects are only now being understood. It is important to understand these agents better so that the potentially large sections of the population who may eventually be eligible to receive therapeutic opioids are treated rationally and safely. RECENT
FINDINGS: Recent advances in pain physiology, molecular biology of neurotransmission, in-vivo neuroimaging and the study of genomic influences on drug receptors and metabolism are beginning to clarify how opioids work, how they differ from each other and how they may cause harm.
SUMMARY: Understanding the biological basis of how opioids work and produce adverse effects should help us to make better choices of which drugs to use for specific populations. Identifying individual genetic differences in opioid receptors and drug metabolism pathways may also pave the way to more targeted and safer medication in the future.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18685352     DOI: 10.1097/SPC.0b013e3282f04e0c

Source DB:  PubMed          Journal:  Curr Opin Support Palliat Care        ISSN: 1751-4258            Impact factor:   2.302


  3 in total

Review 1.  Duloxetine for the treatment of fibromyalgia.

Authors:  Cheryl L Wright; Scott D Mist; Rebecca L Ross; Kim D Jones
Journal:  Expert Rev Clin Immunol       Date:  2010-09       Impact factor: 4.473

Review 2.  [Methylnaltrexone. A new approach for therapy of opioid-induced obstipation].

Authors:  D Chappell; P Conzen
Journal:  Schmerz       Date:  2009-10       Impact factor: 1.107

3.  The relationship between pain, analgesics and survival in patients with advanced cancer; a secondary data analysis of the international European palliative care Cancer symptom study.

Authors:  Jason W Boland; Victoria Allgar; Elaine G Boland; Mike I Bennett; Stein Kaasa; Marianne Jensen Hjermstad; Miriam Johnson
Journal:  Eur J Clin Pharmacol       Date:  2019-12-21       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.